AI assistant
DEXCOM INC — Director's Dealing 2023
Jan 24, 2023
30198_dirs_2023-01-24_f0de12cf-d11f-4d53-b718-d5595523c11a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-01-20
Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman of)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-20 | Common Stock | S | 45607 | $105.7485 | Disposed | 426645 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.